Skip to main content
Moberg Pharma logo

Moberg Pharma — Investor Relations & Filings

Ticker · MOB ISIN · SE0020353928 LEI · 549300XFXK7DVGDRP410 ST Manufacturing
Open in API
Filings indexed 785 across all filing types
Latest filing 2024-03-25 Major Shareholding Noti…
Country SE Sweden
Listing ST MOB

About Moberg Pharma

https://www.mobergpharma.com/

Moberg Pharma is a pharmaceutical company that develops and commercializes proprietary medical products, focusing on innovative drug delivery of proven compounds. The company's primary asset is MOB-015, a topical formulation for the treatment of onychomycosis (nail fungus). MOB-015 has demonstrated high fungal cure rates in Phase 3 clinical trials and has received market approval in multiple European countries. It is commercialized under the brand name Terclara® in Sweden and Norway, where it has achieved market leadership. Moberg Pharma's business model aims for lower development risk and faster market entry than traditional pharmaceutical development. The company's strategic goal is to establish MOB-015 as the leading global treatment for nail fungus.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding, specifically reporting the resulting distribution of total holdings and voting rights after a 'Sell' transaction by a holder (Avanza Bank Holding AB for Avanza Pension). It explicitly mentions 'Reason for major shareholding notification Sell' and provides updated percentages and quantities of shares held. This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to the filing code MRQ.
2024-03-25 English
Valberedningens förslag till årsstämman 2024
AGM Information Classification · 98% confidence The document is titled "Valberedningens förslag till årsstämman 2024" (The Nomination Committee's proposal for the Annual General Meeting 2024). It details proposals regarding the election of the chairman, board members, auditor, and their remuneration for the upcoming Annual General Meeting (AGM). It also outlines the principles for establishing the nomination committee for the following year. This content directly relates to the preparatory materials and proposals presented to shareholders ahead of the AGM, specifically concerning board composition and governance structure, which falls under the scope of AGM-related materials or governance information. Since the core content is the proposal for the AGM elections and governance structure, 'AGM-R' (AGM Information) is the most fitting primary category, as it covers presentations and materials shared during the AGM process. While it touches on governance (CGR), the context is explicitly tied to the upcoming shareholder meeting proposals.
2024-02-19 Swedish
The Nomination Committee’s proposal to the Annual General Meeting 2024
AGM Information Classification · 98% confidence The document is explicitly titled "The Nomination Committee's proposal to the Annual General Meeting 2024" and details proposals regarding the election of the Chairman of the AGM, Board of Directors, Auditor, and associated fees. This content directly relates to the preparatory materials and proposals presented for shareholder voting at the Annual General Meeting (AGM). While it discusses board composition (which could relate to MANG or CGR), the context is strictly the formal proposal package for the AGM. This aligns best with the 'AGM Information' category (AGM-R), which covers presentations and materials shared during the AGM, including the proposals leading up to it.
2024-02-19 English
Earnings Release 2023
Earnings Release Classification · 99% confidence The document is titled "Bokslutskommuniké 2023" (Year-End Report/Financial Statement Release 2023) and presents detailed financial figures for the full year (JAN-DEC 2023) and the fourth quarter (OKT-DEC 2023), including EBITDA, operating result, net result, and EPS. It also includes a CEO commentary and updates on clinical trials and product launches. This structure—a comprehensive summary of annual financial performance combined with operational highlights—is characteristic of an Earnings Release (ER) or a preliminary Annual Report summary, but since it covers the full year and includes detailed financial tables, it aligns best with the initial announcement of annual results. Given the options, 'ER' (Earnings Release) is the most appropriate fit for a 'Bokslutskommuniké' which announces the year-end financial results, even though it is quite detailed. It is not a full 10-K, nor is it just a short announcement of a report (RPA/RNS). It contains the core financial data. If the document were significantly longer and contained all required regulatory disclosures (like a full 10-K), 10-K would be chosen. However, in the context of standard quarterly/annual reporting releases, this functions as the primary Earnings Release for the full year. FY 2023
2024-02-13 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 95% confidence The document is a 'Year-end report 2023' for Moberg Pharma. It contains comprehensive financial data including EBITDA, operating profit, profit after tax, and earnings per share for both the full year and the fourth quarter. It also includes detailed management commentary, operational updates, and business strategy. As it covers a full fiscal year and provides substantive financial statements and analysis, it is classified as an Interim/Quarterly Report (IR) in the context of financial reporting standards for annual/interim periods. FY 2023
2024-02-13 English
MOB-015 is launched in Sweden under the brand name Terclara– pharmacies report major demand for the new medication
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a product (MOB-015 under the brand name Terclara®) in Sweden by a market partner. It contains key business updates, quotes from management (CEO), and information about the product and company. This type of announcement, which details operational progress and market events but is not a formal financial report (like 10-K or IR) or a specific regulatory filing like insider trading or dividend notice, typically falls under general business news or regulatory announcements. Since it is a formal press release detailing a significant business event (product launch and market reception), it is best classified as a general Regulatory Filing (RNS) as it is an official communication to the market, or potentially an Earnings Release (ER) if it were tied to a financial period, but here it is purely operational/commercial. Given the options, RNS serves as the best fit for a general market announcement that doesn't match the more specific categories like DIV, DIRS, or ER (which usually focuses on financial metrics). The length (4709 chars) is substantial enough that it's not just a brief 'publication announcement' (RPA).
2024-02-07 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.